ʻO ka maʻi maʻi pancreatic: nā koho lapaʻau hou

I ke kaua kūʻē i ka maʻi maʻi pancreatic, ua lilo nā hoʻokolohua lapaʻau hou a me nā mea hou. Hāʻawi kēia mau hoʻāʻo i nā poʻe maʻi i ke komo mua ʻana i nā lāʻau lapaʻau ʻokiʻoki i hiki ke alakaʻi i ka holomua i ka noiʻi a me ka manaolana no nā hopena maikaʻi aʻe. 

ʻO kēlā me kēia lāʻau lapaʻau i loaʻa i kēia lā ua noiʻi mua ʻia, hoʻomohala ʻia a ʻae ʻia ma o ka hoʻokolohua lapaʻau - kahi noiʻi noiʻi e noiʻi ana i nā lāʻau lapaʻau hou a i ʻole nā ​​hui pū ʻana o nā lāʻau i loaʻa e hoʻoholo ai inā pono lākou i ka poʻe e noho nei me ka maʻi maʻi pancreatic. Ke ulu nui nei ka maʻi ʻaʻai pancreatic i mea hopohopo nui ma ka honua, e hoʻokau mau ana i ka pono no ka mālama ʻana a me nā hana hoʻomohala lāʻau. ʻO nā pono kūponoʻole e pili ana i ka maʻi e huki ana i nā hui multinational e hoʻokomo i kaʻoihana. ʻO kēia mau mea i hui pū ʻia me ka piʻi ʻana o ka hoʻolimalima olakino olakino e hoʻonui i ka ulu ʻana o ka mākeke. Ua hōʻike ʻia kahi hōʻike mai Global Market Insight e manaʻo ʻia ka nui o ka mākeke mālama maʻi maʻi Pancreatic e hoʻonui i ka loaʻa kālā i ka makahiki 2021 a hiki i 2027. laha i na kino kokoke. ʻO nā koho ola maikaʻi ʻole e like me ka puhi ʻana, ka ʻawaʻawa a me ka ʻai paka a me nā maʻi e pili ana i ka nohona e like me ka momona a me ka maʻi diabetes kekahi o nā kumu nui o ka maʻi maʻi pancreatic. Ua manaʻo ka American Cancer Society e ʻoi aku ma mua o 60,000 ʻAmelika e loaʻa i ka maʻi maʻi pancreatic i 2021. Ke ʻike ʻia nei nā ʻano like ma nā wahi ʻē aʻe o ka honua e hoʻoikaika i nā ʻano ʻoihana. ʻO nā hui biotech a me nā lāʻau lapaʻau ikaika i nā mākeke i kēia pule he Oncolytics Biotech® Inc., Bristol Myers Squibb, Seagen Inc., Exact Sciences Corp., Kura Oncology, Inc.

Ua hoʻohui ʻo Global Market Insight: "Chemotherapy, immunotherapy, target therapy, a me ka hormone therapy, a me nā mea ʻē aʻe, ʻo ia nā ʻano like ʻole o nā koho lapaʻau maʻi pancreatic. Ma waena o kēia mau mea, ʻo ka ʻāpana hoʻomaʻamaʻa i manaʻo ʻia e hopu i ka māhele kūpono o ka mākeke ma 2027. Kuhi ʻia ka lāʻau lapaʻau i nā protein kikoʻī o ka maʻi maʻi, nā genes, a i ʻole nā ​​ʻiʻo e kōkua i ka ulu ʻana o ka maʻi kanesa. Hoʻopaʻa ka lāʻau lapaʻau i ka ulu ʻana a me ka hoʻolaha ʻana o nā maʻi maʻi maʻi ʻoiai e kaupalena ana i ka pōʻino i nā mea olakino. E ʻike ʻia ka lāʻau lapaʻau i hoʻonui ʻia i ka noi no ka mālama ʻana i ka maʻi maʻi pancreatic i nā makahiki e hiki mai ana.

Hāʻawi ʻo Oncolytics Biotech® i ka hoʻomaikaʻi maikaʻi ʻana i ka palekana o ka Pancreatic Cancer Cohort o kāna Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial - Oncolytics Biotech®) i kēia lā i hoʻolaha ai i ka hoʻokō kūleʻa ʻana o ka holo palekana ʻekolu-maʻi no ka hui maʻi maʻi pancreatic o ka pae 1/2 aʻo GOBLET ma hope o ka loiloi ʻana e ka Papa Manaʻo Palekana ʻIkepili (DSMB) o ka noiʻi. ʻAʻole i ʻike ka DSMB i nā hopohopo palekana i kēia mau maʻi a ua ʻōlelo ʻia ka hoʻomau ʻana o ke aʻo ʻana e like me ka mea i hoʻolālā ʻia. Ke hoʻomau nei ka holo ʻana o ka palekana no ke kolu o ka hoʻāʻo ʻana i ka cohort colorectal cancer cohort.

Ke alakaʻi ʻia nei ka haʻawina GOBLET e AIO, kahi hui koʻikoʻi o ka lāʻau lapaʻau oncology koʻikoʻi i hoʻokumu ʻia ma Kelemānia, a ua hoʻolālā ʻia e loiloi i ka palekana a me ka pono o ka pelareorep i hui pū ʻia me ka Roche's anti-PD-L1 checkpoint inhibitor atezolizumab i nā maʻi me ka metastatic pancreatic, metastatic. colorectal, a me na ma'i ma'i ma'i anal holomua. Ke hoʻomau nei ke aʻo ʻana a manaʻo ʻia e kākau inoa i nā mea maʻi ma 14 mau kahua hoʻokolohua lapaʻau ma Kelemania.

Hoʻonui ʻia ka ʻikepili lapaʻau i hōʻike mua ʻia e ka GOBLET study's pancreatic cancer cohort e hōʻike ana i ka synergy a me ka hana anti-cancer o ka pelareorep i hui pū ʻia me ka hoʻopaʻa ʻana i nā mea maʻi maʻi maʻi pancreatic i holomua ma hope o ka lāʻau lapaʻau mua (ka loulou i PR, loulou i ka pepa). Hoʻokumu pū ia ma luna o nā ʻikepili mua mua i hōʻike i ka piʻi ʻana ma mua o 80% o ke ola median progression-free i nā maʻi maʻi maʻi pancreatic me nā haʻahaʻa haʻahaʻa o ka CEACAM6 hōʻike i loaʻa ka pelareorep i hui pū ʻia me ka chemotherapy (ka loulou i PR, loulou i ka pepa). Ma kahi o ka loiloi ʻana i ka palekana a me ka maikaʻi o ka mālama ʻana i ka pelareorep-atezolizumab, ʻimi pū ʻo GOBLET e hōʻike i ka hiki o CEACAM6 a me T cell clonality ma ke ʻano he biomarkers wānana, hiki ke hoʻonui i ka holomua o nā haʻawina hoʻopaʻa inoa e hiki mai ana ma ka ʻae ʻana i ke koho ʻana i nā mea maʻi kūpono loa. .  

Ua hoʻolaha aku nei ʻo Seagen Inc. i ka ʻikepili mai kahi hoʻokolohua lapaʻau pae 1 e hui pū ana i ka SEA-CD40 me ka chemotherapy a me ka anti-PD-1 i nā maʻi me ka metastatic PDAC ma ka hui makahiki ASCO GI e mālama ʻia ana ma Kapalakiko, Ianuali 20 - 22, 2022. SEA -ʻO CD40 he moʻolelo, hoʻokolokolo, nonfucosylated monoclonal receptor-agonistic antibody i kuhikuhi ʻia i CD40, i hōʻike ʻia ma nā cell antigen-presenting. Ma nā hiʻohiʻona preclinical, ʻo ka hui pū ʻana o SEA-CD40 a me ka chemotherapy i hopena i ka hana antitumor i hoʻonui hou ʻia me ka mālama anti-PD-1.

I ka hoʻāʻo ʻana o ka pae 1, ua hui pū ʻia ʻo SEA-CD40 me ka chemotherapy [gemcitabine a me nab-paclitaxel (GnP)], a me kahi anti-PD-1 (pembrolizumab), i nā maʻi 61 me ka PDAC metastatic ʻole i mālama ʻia. ʻO kēia mau mea, loaʻa i nā maʻi 40 ka 10 mcg / kg a me nā maʻi 21 i loaʻa iā 30 mcg / kg o SEA-CD40. Loaʻa nā helu hope nui i hoʻopaʻa ʻia (cORR) no RECIST v1.1 e ka mea noiʻi, progression-free survival (PFS) a me ke ola holoʻokoʻa (OS). Pono ke ola hou aʻe e hoʻomaopopo i kā mākou mau hana e hiki mai ana i ka maʻi maʻi pancreatic, "wahi a Roger Dansey, MD, Luna Kauka Nui ma Seagen. "Ke hoʻomau nei mākou i ka holomua ʻana i ka hoʻāʻo ʻana o ka pae 2 o SEA-CD40 i ka melanoma a me ka maʻi maʻi maʻi pūpū liʻiliʻi ʻole."

Ua hoʻolaha aku nei ʻo Exact Sciences Corp. i ka ʻikepili hana no ka lua o ka hanauna Cologuard (multi-target stool DNA) hōʻike e hōʻike ana i ka naʻau holoʻokoʻa o 95.2% no ka maʻi maʻi colorectal (CRC) ma kahi kikoʻī o 92.4% no nā laʻana maikaʻi ʻole i hōʻoia ʻia e ka colonoscopy. Ua hōʻike ʻia nā loiloi subgroup he 83.3% ka naʻau no ka dysplasia kiʻekiʻe, nā ʻeha precancerous weliweli loa, a me 57.2% no nā ʻeha precancerous holomua āpau. E hōʻike ʻia kēia mau ʻikepili ma Ianuali 22 ma ASCO GI ma kahi pepa i kapa ʻia, "ʻO ka lua o nā hanauna he nui-target Stool DNA Panel hilinaʻi e ʻike i ka maʻi maʻi colorectal a me nā lesion precancerous kiʻekiʻe."

ʻO Cologuard ka mua a ʻo ka FDA wale nō i ʻāpono ʻia, ʻaʻole invasive stool DNA hoʻāʻo i hoʻohana ʻia e nānā i ka poʻe awelika-pilikia no CRC. Ke hoʻomohala nei ʻo Exact Science i ka lua o ka hanauna Cologuard e hoʻomaikaʻi i ka kikoʻī a me ka naʻau precancer o ka hoʻāʻo, e hoʻemi ana i ka helu kūpono wahaheʻe a me ka hoʻonui ʻana i ka helu ʻike o nā leona precancerous. Hōʻike ka haʻawina i ka hiki o kahi papa hoʻokaʻawale loa o nā māka DNA methylated a me fecal hemoglobin e hoʻokō i nā mea ʻelua i kahi kūlana honua maoli. Inā ʻae ʻia, hiki i ka hoʻāʻo ʻo Cologuard ka lua o ka hanauna ke kōkua i ka hoʻonui ʻana i ka helu screening ʻoiai e hoʻouna ana i nā poʻe liʻiliʻi e hahai i nā colonoscopies me ka pono ʻole a me ka ʻike ʻana i nā precancers ʻoi aʻe ma mua o ka holomua ʻana i ka maʻi kanesa, e kōkua ana i ka pale ʻana i ka maʻi.

Ua hoʻolaha koke aku ʻo Bristol Myers Squibb i ke Kōmike no nā huahana lāʻau lapaʻau no ka hoʻohana ʻana i ke kanaka (CHMP) o ka European Medicines Agency (EMA) ua ʻae aku i ka ʻae ʻana o Breyanzi (lisocabtagene maraleucel; liso-cel), kahi CD19-directed chimeric antigen receptor (CAR) T cell. ka lāʻau lapaʻau no ka mālama ʻana i nā poʻe maʻi makua me ka relapsed a refractory (R/R) diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), a me ka follicular lymphoma grade 3B (FL3B) ma hope o ʻelua a ʻoi mau laina. ʻo ka hoʻoponopono ʻōnaehana. E nānā ʻia ka ʻōlelo aʻoaʻo CHMP e ka European Commission (EC), nona ka mana e ʻae i nā lāʻau lapaʻau no ka European Union (EU).

ʻO Kura Oncology, Inc., he hui lāʻau biopharmaceutical i hoʻopaʻa ʻia e hoʻokō i ka ʻōlelo hoʻohiki o nā lāʻau lapaʻau pololei no ka mālama ʻana i ka maʻi maʻi maʻi, ua hoʻolaha koke nei ua hāpai ka US Food and Drug Administration (FDA) i ka paʻa ʻana o ka lāʻau lapaʻau ma ka KOMET-001 Phase 1b ke aʻo ʻana o KO-539 i nā maʻi me ka relapsed a refractory acute myeloid leukemia (AML). Ua hoʻokiʻekiʻe ʻia ka paʻa ʻāpana ma hope o ka ʻaelike me ka FDA ma ka hoʻolālā mitigation a ka Hui no ka maʻi ʻokoʻa, kahi hanana ʻino i ʻike ʻia e pili ana i nā mea hoʻokaʻawale i ka mālama ʻana i ka AML.